Condition (MeSH)
Papillon-Lefevre Disease
ClinicalTrials.gov lists 2 trials for Papillon-Lefevre Disease or a narrower condition beneath it. Hope Biosciences Research Foundation has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Papillon-Lefevre Disease itself; the rest are tagged with a narrower condition beneath it.
When did Papillon-Lefevre Disease trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2006 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Papillon-Lefevre Disease trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Observational | 1 |
| Expanded access | 1 |
How many Papillon-Lefevre Disease trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| No longer available | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Papillon-Lefevre Disease trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hope Biosciences Research Foundation | 1 |
Which publications cover Papillon-Lefevre Disease? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treatment of patient with Papillon-Lefevre syndrome with short dental implants: a case report. | Implant dentistry | 2010 | Yes |
| Functional Cathepsin C mutations cause different Papillon-Lefèvre syndrome phenotypes. | Journal of clinical periodontology | 2008 | Yes |
| Role of polymorphonuclear leukocyte-derived serine proteinases in defense against Actinobacillus actinomycetemcomitans. | Infection and immunity | 2006 | Yes |
| Periodontal therapy in siblings with Papillon-Lefèvre syndrome and tinea capitis: a report of two cases. | Journal of clinical periodontology | 2006 | Yes |
| Orthodontic treatment in a patient with Papillon-Lefèvre syndrome. | Journal of periodontology | 2005 | Yes |
Showing 5 of 7 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Papillon-Lefèvre syndrome | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Papillon-Lefèvre syndrome | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Papillon-Lefèvre syndrome | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Papillon-Lefèvre syndrome | 678 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Papillon-Lefèvre syndrome | 678 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.